GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CEO Katherine Stueland sold 1,078 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $89.44, for a total value of $96,416.32. Following the transaction, the chief executive officer now directly owns 6,674 shares of the company’s stock, valued at approximately $596,922.56. This represents a 13.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Katherine Stueland also recently made the following trade(s):
- On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $1,021,160.89.
- On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The shares were sold at an average price of $94.73, for a total value of $258,707.63.
- On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36.
- On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60.
- On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total transaction of $1,407,709.08.
GeneDx Price Performance
WGS stock opened at $94.46 on Tuesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company’s 50-day moving average is $84.69 and its 200-day moving average is $70.37. The stock has a market capitalization of $2.65 billion, a PE ratio of -48.19 and a beta of 1.91. GeneDx Holdings Corp. has a 1 year low of $7.72 and a 1 year high of $115.60.
Analyst Ratings Changes
A number of research analysts have recently issued reports on WGS shares. The Goldman Sachs Group boosted their price objective on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen lifted their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $72.33.
Check Out Our Latest Report on WGS
Institutional Trading of GeneDx
Several hedge funds have recently bought and sold shares of WGS. Vanguard Group Inc. raised its holdings in GeneDx by 18.5% during the fourth quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company’s stock worth $77,337,000 after buying an additional 156,768 shares during the last quarter. Summit Partners Public Asset Management LLC raised its holdings in shares of GeneDx by 336.9% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock worth $58,073,000 after acquiring an additional 582,619 shares during the last quarter. William Blair Investment Management LLC acquired a new stake in shares of GeneDx in the 4th quarter worth about $51,496,000. Lord Abbett & CO. LLC bought a new position in GeneDx in the 4th quarter valued at about $48,458,000. Finally, Fred Alger Management LLC boosted its stake in GeneDx by 38.5% during the 4th quarter. Fred Alger Management LLC now owns 546,054 shares of the company’s stock valued at $41,970,000 after purchasing an additional 151,824 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.
GeneDx Company Profile
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Recommended Stories
- Five stocks we like better than GeneDx
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Can TikTok Stock Picks Really Make You Rich?
- What is a Dividend King?
- The “Quality” Rotation: Back to Basics Investing
- What is the FTSE 100 index?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.